Epigenetic reversal of acquired resistance to 5-fluorouracil treatment

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1045-1054

  Humeniuk, Rita ^a,c   Mishra, Prasun J ^a,c   Bertino, Joseph R ^b   Banerjee, Debabrata ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; FLUOROURACIL; FLUOROURIDINE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; URIDINE PHOSPHATE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER RESISTANCE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENOMICS; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ORDER; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NUCLEOSIDE-PHOSPHATE KINASE; PROMOTER REGIONS, GENETIC; RNA STABILITY; URIDINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66849111560     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0717     Document Type: Conference Paper

References (45)

1. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428 (Pubitemid 34587077)
3. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007;61:24-9R.
4. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol 2004;14:427-432 (Pubitemid 39360990)
5. Jen J, Powell SM, Papadopoulos N, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994;54:5523-5526 (Pubitemid 24346238)
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054 (Pubitemid 37448928)
7. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21. (Pubitemid 34049633)
8. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116
9. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681-8686 (Pubitemid 29354851)
10. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-793 (Pubitemid 43980599)
11. Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 2004;84:884-893 (Pubitemid 38833248)
12. Deng G, Song GA, Pong E, Sleisenger M, Kim YS. Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. Cancer Res 2004;64:2692-2698 (Pubitemid 38500603)
13. Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006;25:4116-4121 (Pubitemid 44024874)
14. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003;106:66-73. (Pubitemid 36750389)
15. Deng G, Chen A, Pong E, Kim YS. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene 2001;20:7120-7127 (Pubitemid 33052206)
16. 0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology 1999;57:149-156
17. Jacinto FV, Ballestar E, Ropero S, Esteller M. Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res 2007;67:11481-11486
18. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006;94:1087-1092
19. Wei SH, Brown R, Huang TH. Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann N Y Acad Sci 2003;983:243-250
20. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-211 (Pubitemid 32144287)
21. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-5877 (Pubitemid 32937956)
22. Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998;92:4296-4307 (Pubitemid 28544347)
23. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004;10:4420-4426 (Pubitemid 38878884)
24. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803
25. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006;12:5777-5785 (Pubitemid 44629609)
26. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-6044
27. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007;25:4603-4609 (Pubitemid 350035319)
28. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992;52:1855-1864.
29. Pizzorno G, Handschumacher RE. Effect of clinically modeled regimens on the growth response and development of resist ance in human colon carcinoma cell lines. Biochem Pharmacol 1995;49:559-565
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDC(T)) method. Methods 2001;25:402-408 (Pubitemid 34164012)
31. Leclerc GJ, Leclerc GM, Barredo JC. Real-time RT-PCR analysis of mRNA decay: half-life of β-actin mRNA in human leukemia CCRF-CEM and Nalm-6 cell lines. Cancer Cell Int 2002;2:1. (Pubitemid 38751051)
32. Belinski SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003;63:7089-7093 (Pubitemid 37413444)
33. Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 2000;16:276-277
34. Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin Hematol 2005;42:S17-22. (Pubitemid 40961868)
35. Wilkinson DS, Tlsty TD, Hanas RJ. The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine. Cancer Res 1975;35:3014-3020
36. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338 (Pubitemid 37328853)
37. Pasetto LM, Bortolami A, Falci C, Sinigaglia G, Monfardini S. Recent progress in target therapy in colorectal cancer. Anticancer Res 2006;26:3973-3981 (Pubitemid 44701485)
38. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-237 (Pubitemid 19114713)
39. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer- a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-381 (Pubitemid 27020595)
40. Fang F, Hoskins J, Butler JS. 5-Fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs. Mol Cell Biol 2004;24:10766-10776 (Pubitemid 39603133)
41. Zhu WG, Dai Z, Ding H, et al. Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene 2001;20:7787-7796 (Pubitemid 33121952)
42. Hummel M, Yan S, Li Z, Varghese TK, Abecassis M. Transcriptional reactivation of murine cytomegalovirus in gene expression by 5-aza-2′- deoxycytidine and trichostatin A in latently infected cells despite lack of methylation of the major immediate-early promoter. J Gen Virol 2007;88:1097-1102 (Pubitemid 46523497)
43. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006;66:5021-5028 (Pubitemid 43844922)
44. Karpf A R, Peterson PW, Rawlins JT, et al. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A 1999;96:14007-14012
45. Mikovits JA, Young HA, Vertino P, et al. Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the γ interferon (IFN-γ) promoter and subsequent downregulation of IFN-γ production. Mol Cell Biol 1998;18:5166-5177 (Pubitemid 28388100)